Baralyme Agreement (Tables)

3 Months Ended

Sep. 30, 2012

Deferred Revenue Disclosure [Abstract]

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

A reconciliation of deferred revenue resulting from the agreement with Abbott Laboratories (“Abbott”), with the amounts received under the agreement, and amounts recognized as net sales is as follows:

	Three Months ended
	September 30,
	2012			2011
Beginning balance	$	114,700		$	802,900
Revenue recognized  as net sales		(114,700	)		(172,050	)
		0			630,850
Less - Current portion of deferred revenue		0			(630,850	)
	$	-		$	-